Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani, ML Keohan… - Lung Cancer, 2007 - Elsevier
BACKGROUND: An expanded access program (EAP) provided patient access to
pemetrexed prior to its commercial availability. The current report consists of US patients in …
被引用次数：36 相关文章

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani, ML Keohan… - Lung Cancer, 2007 - infona.pl
An expanded access program (EAP) provided patient access to pemetrexed prior to its
commercial availability. The current report consists of US patients in the EAP who had …

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak… - Lung cancer …, 2007 - pubmed.ncbi.nlm.nih.gov
Background An expanded access program (EAP) provided patient access to pemetrexed
prior to its commercial availability. The current report consists of US patients in the EAP who …

[引用][C] Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: Outcomes of an expanded …

CK OBASAJ, Z YE, AJ WOZNIAK, CP BELANI… - Lung …, 2007 - pascal-francis.inist.fr
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with
malignant pleural mesothelioma : Outcomes of an expanded access program CNRS Inist …

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani… - Lung Cancer …, 2006 - europepmc.org
Background An expanded access program (EAP) provided patient access to pemetrexed
prior to its commercial availability. The current report consists of US patients in the EAP who …

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani… - Lung …, 2007 - mayoclinic.elsevierpure.com
Background: An expanded access program (EAP) provided patient access to pemetrexed
prior to its commercial availability. The current report consists of US patients in the EAP who …

[引用][C] Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani, ML Keohan… - Lung Cancer, 2007 - cir.nii.ac.jp
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients
with malignant pleural mesothelioma: Outcomes of an expanded access program | CiNii …

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani… - Lung Cancer, 2007 - pure.psu.edu
Background: An expanded access program (EAP) provided patient access to pemetrexed
prior to its commercial availability. The current report consists of US patients in the EAP who …

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access …

CK Obasaju, Z Ye, AJ Wozniak, CP Belani… - Lung …, 2007 - lungcancerjournal.info
Background An expanded access program (EAP) provided patient access to pemetrexed
prior to its commercial availability. The current report consists of US patients in the EAP who …

[引用][C] Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: Outcomes of an expanded …

CK OBASAJ, YE ZHISHEN, AJ WOZNIAK, CP BELANI… - Lung cancer, 2007 - Elsevier